Who Paid My Doc
Saju Joseph
Surgical Oncology Las Vegas, NV Medical Doctor
NPI 1083870554 CMS profile 1219929
5380 S Rainbow Blvd Ste 330, Las Vegas, NV 89118
General payments
$175,651
Research payments
$0
Ownership & investment interest
$0
Research they led as principal investigator
$6,450
Through program year 2025, Saju Joseph of Las Vegas, NV is reported in the CMS Open Payments database as having received $175,651 across 123 general payments and $0 in research payments paid to them. Separately, studies naming them as principal investigator received $6,450 in research payments, paid to institutions rather than to them.
No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them. The principal-investigator line is research money paid to institutions for studies they led — not to them — and is not added to anything either.
General payments for this record sit in the 98th percentile of Surgical Oncology profiles with reported payments. Percentile describes the distribution, not the conduct.
By program year
7 rows| Year | Kind | Relative to this record's peak year | Amount | Records |
|---|---|---|---|---|
| 2025 | General | $25,621 | 16 | |
| 2024 | General | $52,072 | 24 | |
| 2023 | General | $55,357 | 26 | |
| 2022 | General | $37,308 | 29 | |
| 2021 | General | $4,453 | 19 | |
| 2020 | General | $814 | 7 | |
| 2019 | General | $26 | 2 |
Beside peers
- Saju Joseph
- Surgical Oncology median
- Middle half of Surgical Oncology
- National median
In program year 2025, general payments to Saju Joseph were reported at $25,621. Among 1,137 Surgical Oncology profiles paid that year, the median was $288 and the middle half received between $118 and $1,346.
Show as a table
| Year | Saju Joseph | Surgical Oncology median | Middle half | National median |
|---|---|---|---|---|
| 2019 | $26 | $236 | $86–$1,064 | $163 |
| 2020 | $814 | $130 | $47–$648 | $114 |
| 2021 | $4,453 | $160 | $53–$943 | $132 |
| 2022 | $37,308 | $199 | $76–$782 | $149 |
| 2023 | $55,357 | $246 | $95–$854 | $160 |
| 2024 | $52,072 | $271 | $106–$1,123 | $164 |
| 2025 | $25,621 | $288 | $118–$1,346 | $169 |
Breakdown
A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.
Billing to Medicare
Part B · data year 2024 · 27 billing codesPaid by Medicare
$9,533
Medicare patients
31
Services billed
63
| Condition among their Medicare patients | Relative to the most common | Share of patients |
|---|---|---|
| High blood pressure | 75% | |
| Arthritis | 48% | |
| Ischemic heart disease | 39% | |
| Chronic kidney disease | 35% |
Medicare Part B only: services billed to Medicare. Rows covering fewer than 11 beneficiaries are not published. Only drugs given in the clinic are itemised here; the rest of what this provider billed is in the total above.
Records
123 reportedEvery payment, record by record
Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.
Other Surgical Oncology in Nevada
Related records
Surgical Oncology in Nevada
Practitioners in the same specialty and state, ranked by reported value.
All Surgical Oncology
Everyone recorded under this specialty, nationwide.
Doctors in Nevada
Every practitioner in the state with a reported payment.
How to read this page
What each amount means, and what it does not mean.
What this means
U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.
An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.
Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.